Phospholipid Type Regulates Protein Corona Composition and In Vivo Performance of Lipid Nanodiscs
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c01084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Feng Pan und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education & Department of Pharmacy, Jing'an District Central Hospital of Shang…. Hauptthemen laut MEDLINE: Protein Corona, Phospholipids, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Over the years, there has been significant interest in PEGylated lipid-based nanocarriers within the drug delivery field. The inevitable interplay between the nanocarriers and plasma protein plays a pivotal role in their in vivo biological fate. Understanding the factors influencing lipid-based nanocarrier and protein corona interactions is of paramount importance in the design and clinical translation of these nanocarriers. Herein, discoid-shaped lipid nanodiscs (sNDs) composed of different phospholipids with varied lipid tails and head groups were fabricated. We investigated the impact of phospholipid components on the interaction between sNDs and serum proteins, particle stability, and biodistribution. The results showed that all of these lipid nanodiscs remained stable over a 15 day storage period, while their stability in the blood serum demonstrated significant differences. The sND composed of POPG exhibited the least stability due to its potent complement activation capability, resulting in rapid blood clearance. Furthermore, a negative correlation between the complement activation capability and serum stability was identified. Pharmacokinetic and biodistribution experiments indicated that phospholipid composition did not influence the capability of sNDs to evade the accelerated blood clearance phenomenon. Complement deposition on the sND was inversely associated with the area under the curve. Additionally, all lipid nanodiscs exhibited dominant adsorption of apolipoprotein. Remarkably, the POPC-based lipid nanodisc displayed a significantly higher deposition of apolipoprotein E, contributing to an obvious brain distribution, which provides a promising tool for brain-targeted drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education & Department of Pharmacy, Jing'an District Central Hospital of Shanghai Fudan University, Shanghai 201203, P. R. China.
- Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center & Department of Pharmacology School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers, Fudan U…
ORCID-Profile: Xiaoli Wei, Changyou Zhan, Jun Qian
Förderung
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
Zitieren
APA
Pan, F., Liu, M., Li, G., Chen, B., Chu, Y., Yang, Y., Wu, E., Yu, Y., Lin, S., Ding, T., Wei, X., Zhan, C., & Qian, J. (2024). Phospholipid Type Regulates Protein Corona Composition and In Vivo Performance of Lipid Nanodiscs. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c01084
Vancouver
Pan F, Liu M, Li G, Chen B, Chu Y, Yang Y, et al. Phospholipid Type Regulates Protein Corona Composition and In Vivo Performance of Lipid Nanodiscs. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c01084
BibTeX
@article{Pan2024,
author = {Pan, Feng and Liu, Mengyuan and Li, Guanghui and Chen, Boqian and Chu, Yuxiu and Yang, Yang and Wu, Ercan and Yu, Yifei and Lin, Shiqi and Ding, Tianhao and Wei, Xiaoli and Zhan, Changyou and Qian, Jun},
title = {Phospholipid Type Regulates Protein Corona Composition and In Vivo Performance of Lipid Nanodiscs},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c01084}
}
EUVIMED